Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Cytarabine mixture with daunonubicin
RN: 1256639-86-7


  • NCI: A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposomal cytarabine-daunorubicin CPX-351 has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids. (NCI Thesaurus)

Molecular Formula

  • C27-H29-N-O10.C9-H13-N3-O5

Molecular Weight

  • 770.7408

Classification Code

  • Antineoplastic Agents
* denotes mobile formatted website

Links to Resources

Search for this InChIKey on the Web

Names and Synonyms

Results Name

  • Cytarabine mixture with daunonubicin


  • CPX 351
  • CPX-351
  • Cytarabine / daunonubicin
  • Daunonubicin / cytarabine
  • Daunonubicin and cytarabine liposomal injection
  • Daunonubicin mixture with cytarabine
  • Vyxeos

Systematic Name

  • 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone

Registry Numbers

CAS Registry Number

  • 1256639-86-7

System Generated Number

  • 1256639867

Molecular Formulas

Molecular Formula

  • C27-H29-N-O10.C9-H13-N3-O5

Molecular Formula Fragments

  • C27-H29-N-O10
  • C9-H13-N3-O5

Structure Descriptors